info@marketresearchfuture.com   đź“ž  +1 (855) 661-4441(US)   đź“ž  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Chronic Idiopathic Constipation Companies

Addressing gastrointestinal health, Chronic Idiopathic Constipation companies specialize in the research and development of effective treatments. These companies strive to provide solutions that alleviate symptoms and enhance the overall well-being of individuals with chronic constipation.

Chronic Idiopathic Constipation Market

 


Latest Chronic Idiopathic Constipation Companies Updates:


Suven Therapeutics: Received FDA approval for SB207798, a first-in-class, peripherally acting G-protein coupled receptor 54 (GPR54) agonist, for treating CIC in adults.


Evoke Pharma: Launched Moviprep HCT, a new bowel preparation option for colonoscopy in CIC patients.


Iterum Therapeutics: Announced positive Phase 2b data for ITR-603, a novel, non-stimulant oral medication for treating CIC.


Almirall acquired Takeda's gastroenterology portfolio, including Movicol, a leading osmotic laxative used in CIC treatment.


Exelixis and Zai Lab entered into a collaboration to develop and commercialize Zai Lab's ET701, a potential first-in-class guanylate cyclase-C (GC-C) stimulator for treating CIC.


List of Chronic Idiopathic Constipation Key companies in the market:



  • Pfizer Inc (U.S.)

  • Progenics Pharmaceuticals (U.S.)

  • GlaxoSmithKline (U.K.)

  • Sucampo Pharmaceuticals Inc (U.S.)

  • Ironwood Pharmaceuticals (U.S.)

  • Sanofi (France)

  • Salix Pharmaceuticals Ltd (U.S.)

  • Bayer (Germany)


Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.